Elata 6.5mg Tablet

Introduction

Elata is a prescription medication that contains the active ingredient Ulipristal acetate. It is available under the brand name Elata. This medication is primarily used for the management of certain gynecological conditions.

Uses

Elata is prescribed for the treatment of uterine fibroids, which are noncancerous growths in the uterus. It can also be used for the preoperative treatment of moderate to severe symptoms of uterine fibroids to help improve anemia caused by heavy menstrual bleeding.

Dosage and Administration

The recommended dosage of Elata is one tablet (5 mg) taken orally with water. It should be taken with or without food. Your healthcare provider will determine the duration of treatment based on your specific condition.

Mechanism of Action

Ulipristal acetate, the active ingredient in Elata, works by binding to the progesterone receptors in the uterus. This helps to regulate hormone levels and reduce the size of uterine fibroids. It also helps to alleviate symptoms associated with uterine fibroids, such as heavy menstrual bleeding.

Side Effects

Common side effects may include headache, nausea, abdominal pain, and menstrual changes. These side effects are generally mild and temporary.

However, be aware of serious side effects that may occur. Seek medical attention immediately if you experience severe abdominal pain, persistent nausea or vomiting, jaundice (yellowing of the skin or eyes), or any signs of an allergic reaction (such as rash, itching, or swelling).

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. Certain medications may interact with Elata, potentially affecting its effectiveness or causing adverse effects. Some examples of medications that may interact with Elata include rifampin, phenytoin, and St. John’s wort. Your healthcare provider can provide more information on potential drug interactions.

Precautions

Before taking Elata, inform your healthcare provider about any underlying medical conditions, allergies, or if you are pregnant or breastfeeding. This medication is not recommended for use during pregnancy, as it may harm the developing fetus. It is also not recommended for use while breastfeeding, as it may pass into breast milk.

Elata should be used with caution in patients with liver or kidney impairment. Your healthcare provider will monitor you closely while you are taking this medication.

Storage

Elata should be stored at room temperature, away from moisture and heat. Keep it out of the reach of children and pets. Do not use the medication if it has expired or if the packaging is damaged.

Patient Tips

Here are some tips to help you make the most of your treatment with Elata:

• Take the medication as prescribed by your healthcare provider. Do not exceed the recommended dosage.
• If you miss a dose, take it as soon as you remember. If it is close to the time for your next dose, skip the missed dose and resume your regular dosing schedule.
• Do not stop taking Elata without consulting your healthcare provider, even if you start feeling better.
• If you have any concerns or questions about your treatment, do not hesitate to reach out to your healthcare provider for clarification.
• Follow a healthy lifestyle, which includes regular exercise, a balanced diet, and adequate rest, to support your overall well-being.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• About medroxyprogesterone tablets (NHS UK) [Accessed 0 Jun. 2024] (online) Available at:
• Esmya 5 mg Tablets (ulipristal acetate) (Health Professionals SmPC) Available at:
• Ulipristal (Drugs.com) [Accessed 7 Jun. 2024] (online) Available at:
• Birth Control (Food and Drug Administration) [Accessed 25 Jun. 2024] (online) Available at:
• Gonçalves-Henriques M, de Pinho A, Freixo M, Liz-Coelho M, Castro F, Ceschin N, Brandão P. Ulipristal Acetate in Adenomyosis. Gynecol Minim Invasive Ther. 2022 Oct 7;11(4):198-202. doi: 10.4103/gmit.gmit_95_21. eCollection 2022 Oct-Dec. [Accessed 16 Jun. 2024] Available at: